地屈孕酮结构式
|
常用名 | 地屈孕酮 | 英文名 | Dydrogesterone |
---|---|---|---|---|
CAS号 | 152-62-5 | 分子量 | 312.446 | |
密度 | 1.1±0.1 g/cm3 | 沸点 | 462.8±45.0 °C at 760 mmHg | |
分子式 | C21H28O2 | 熔点 | 168-173°C | |
MSDS | N/A | 闪点 | 172.2±25.7 °C |
地屈孕酮用途Dydrogesterone(Duphaston)是口服活性的孕激素,可作用于孕酮缺乏相关疾病。 |
中文名 | 去氢孕酮 |
---|---|
英文名 | dydrogesterone |
中文别名 | 6-去氢逆孕酮 | 盐酸丙环定.盐酸吡哌立登 | 地屈孕酮 |
英文别名 | 更多 |
密度 | 1.1±0.1 g/cm3 |
---|---|
沸点 | 462.8±45.0 °C at 760 mmHg |
熔点 | 168-173°C |
分子式 | C21H28O2 |
分子量 | 312.446 |
闪点 | 172.2±25.7 °C |
精确质量 | 312.208923 |
PSA | 34.14000 |
LogP | 3.58 |
蒸汽压 | 0.0±1.1 mmHg at 25°C |
折射率 | 1.557 |
储存条件 | Refrigerator |
分子结构 | 1、 摩尔折射率:66.79 2、 摩尔体积(cm3/mol):179.4 3、 等张比容(90.2K):486.1 4、 表面张力(dyne/cm):53.8 5、 极化率(10-24cm3):26.48 |
计算化学 | 1.疏水参数计算参考值(XlogP):3.8 2.氢键供体数量:0 3.氢键受体数量:2 4.可旋转化学键数量:1 5.互变异构体数量:21 6.拓扑分子极性表面积34.1 7.重原子数量:23 8.表面电荷:0 9.复杂度:628 10.同位素原子数量:0 11.确定原子立构中心数量:6 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 | 1.熔点(℃):168-173。 |
安全声明 (欧洲) | S26-S37/39 |
---|---|
危险品运输编码 | 3276 |
WGK德国 | 3 |
包装等级 | III |
危险类别 | 6.1 |
地屈孕酮上游产品 1 | |
---|---|
地屈孕酮下游产品 0 |
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Gynecol. Endocrinol. 29(2) , 165-8, (2013) It is established that hormone therapy (HT) is related with significant increased prothrombotic risk factor. The aim of our study was to assess the effects of oral hormone therapy (o-HT) and transderm... |
|
Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety.
Maturitas 76(1) , 10-21, (2013) HRT is known to be effective for the relief of menopausal symptoms and prevention of osteoporosis. HRT should be tailored to the woman, enhancing the beneficial effects of the treatment while minimizi... |
|
Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.
Neuro Endocrinol. Lett. 33(7) , 697-702, (2012) Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due t... |
Dydrogesterone |
D6-Retroprogesterone |
δ6-Retroprogesterone |
9β,10α-Pregna-4,6-diene-3,20-dione (8CI) |
9b,10a-Pregna-4,6-diene-3,20-dione |
(8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one |
(9β,10α)-Pregna-4,6-diene-3,20-dione |
EINECS 205-806-8 |
6-Dehydro-9b,10a-progesterone |
MFCD00867864 |
10a-Isopregnenone |
6-Dehydroretroprogesterone |
6-Dehydro-9β,10α-progesterone |
(9b,10a)-Pregna-4,6-diene-3,20-dione |
Pregna-4,6-diene-3,20-dione, (9β,10α)- |